In addition, an anti-IL-33 monoclonal antibody is in a phase 2 clinical trial for peanut allergy (http://Clinicaltrials.gov, NCT02920021) and also in phase 2 trials for AD (EU Clinical Trials Register number 2016-002539-14). The gene discussed is IL33; the disease is Alzheimer disease.